|
|
楼主 |
发表于 2025-2-21 00:22:58
|
显示全部楼层
马骏院士团队被接收一篇JAMA、一篇Cancer Cell，另有8项临床试验在进行中
$ v# b5 G) O$ ^- b' v0 E3 X: oWhole-course Concurrent and Adjuvant Nivolumab Combined with Induction Chemotherapy Followed by Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma (NCT03984357, Cancer Cell, 2025,已接收)
3 c9 V( |5 N p
6 p( p D# ^' a$ x/ CAdjuvant PD-1 Antibody in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Randomised Controlled, Phase 3 Trial (NCT03427827, JAMA, 2025,已接收)
{7 N# ]4 v8 [; V, `- t2 M2 u- _/ }) z8 R$ r
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma (NCT06455410, 进行中)
# r1 U! J! @* V7 j3 y) d) n5 HIndividualized Elective Neck Irradiation in NPC Patients (NCT06241612, 进行中)
F2 o3 s. w7 gReduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response (NCT06239727, 进行中)- ]4 @2 l' [) I# @2 f. d
Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma (NCT05587374, 进行中)
+ }9 p: Q5 P/ a' DTQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT05563480, completed)
! E5 ]' Z0 W1 kCombining MRI and CEUS to Diagnose Small Cervical Lymph Node Metastases in NPC Patients (NPC-LN) (NCT05389306, 进行中)+ U7 O5 A( V; X1 D
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma (NCT05342792, 进行中)
- U2 p& m( e) p' _Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) (NCT05044117, 进行中) |
|
发表于 2025-2-20 23:39:43
